The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan versus docetaxel in patients with metastatic castration-resistant prostate cancer with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifinatamab deruxtecan is a specifically engineered B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck (MRK).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Zoetis downgraded to Hold from Buy at Stifel
- Trump administration weighs crackdown on pharma ads, Bloomberg says
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
- Merck says FDA approves Keytruda for treatment of HNSCC
- Merck Animal Health receives EU CVMP positive opinion for NUMELVI